(Lung Cancer) Is Anti-B7-H3 Antibody Drug DS-7300 Effective?
(Lung Cancer) Is Anti-B7-H3 Antibody Drug DS-7300 Effective?
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
(Lung Cancer) Is Anti-B7-H3 Antibody Drug DS-7300 Effective?
- September 25, 2023
- 1 min read
From September 9-12, 2023, Daiichi Sankyo presented results at the World Conference on Lung Cancer held in Singapore on the efficacy and safety of anti-B7-H3 antibody drug DS-7300 in a Phase 1/2 clinical trial for advanced small cell lung cancer patients with multiple prior treatment histories.
The trial also enrolled other advanced solid tumor patients with multiple prior treatment histories. The primary endpoints included dose-limiting toxicity, safety, and anti-tumor efficacy. Analysis results for the small cell lung cancer cohort showed that among the 21 enrolled patients, the objective response rate was 52.4%, with 1 complete response and 10 partial responses. The median duration of response was 5.9 months, the median progression-free survival was 5.6 months, and the median overall survival was 12.2 months.
Regarding safety, the findings were consistent with the safety profile observed in existing clinical data. No new adverse reactions were identified in this trial. The incidence of grade 3 or higher adverse events was 36.4%, with 1 case of drug-related interstitial lung disease classified as grade 2.
Based on the trial results, Daiichi Sankyo stated in its press release that it will continue conducting Phase II clinical trials targeting advanced small cell lung cancer patients based on these results and accelerate the development of this drug.
Source: https://www.daiichisankyo.co.jp/files/news/pressrelease/pdf/202309/20230911_J1.pdf
-
Investigational drug
(Lung Cancer) Topotecan and Topotecan + Berzosertib Treatment Results in Phase II Clinical Trial. (Lung Cancer) Is Trastuzumab deruxtecan Effective for HER2-Mutant Non-Small Cell Lung Cancer? (Lung Cancer) Is Alectinib Effective?
Medical Supporter was formerly certified as a medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free (initial direction only; further services are quoted separately); an advisor will help you clarify the next steps.